INTER-Regional COHORTE Of Long Term Pancreatic Cancer Survivors

Study Overview

INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors

The study is particularly innovative as it will accurately analyze the microscopic characteristics of the stroma, tumor budding and mucin expression in adenocarcinomas of the pancreas, using a comparative approach of long-survivor/short-survival patients.

N/A

Pancreas Cancer
Pancreatic Adenocarcinoma

2019_29
2019-A02001-56 (OTHER Identifier) (OTHER: ID-RCB number,ANSM)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2020-06-15	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-03-25
First Submitted that Met QC Criteria 2020-06-15	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-03-30
First Posted (ACTUAL) 2020-06-18	Results First Posted N/A	Last Verified 2025-03

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Primary Outcome Measures	Measure Description	Time Frame
Relationship between known prognostic histological markers of pancreatic adenocarcinoma and patient survival.	Tissue analysis will be performed by conventional microscopy and will evaluate histological markers known in the literature to have a prognostic impact.	at 2 years

Secondary Outcome Measures	Measure Description	Time Frame
Relationship between newly described histological markers for pancreatic adenocarcinoma and patient survival.	Immunohistochemistry tissue analysis. It will allow the evaluation of newly described histological markers for pancreatic adenocarcinoma, which could have a prognostic impact such as the immunophenotype of the inflammatory infiltrate, the expression of the mucins MUC1, MUC5AC, MUC4, MUC16, mesothelin, p53, Ki67 (MIB1) and markers of aggressive subtypes identified by transcriptome studies, in particular the basal-like molecular subtype.	at 2 years

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

Patients > 18 years of age at diagnosis
Primary pancreatic cancer patients operated on in one of the 4 centres between 2001 and 2016
Histopathological diagnosis of excreto-pancreatic adenocarcinoma of the pancreas, ductal adenocarcinoma or classical adenocarcinoma
Tissue blocks (FFPE) available (tumour/healthy tissue)
Affiliated to a social security scheme

Absence of Primary Cancer Tissue Blocks (PCTBs)
Paraffin block fixed in Bouin or AFA
Patient Refusal
Pancreatic cancer not corresponding to a conventional excretopancreatic adenocarcinoma such as: carcinoma on intraductal papillary mucinous neoplasm, endocrine tumor/carcinoma, acinar cell carcinoma, ...).
Patient died due to post-surgical complications (death within 30 days post-surgery).
Surgical resection of macroscopic R2 type.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

PRINCIPAL_INVESTIGATOR: Emmanuelle Leteurtre, MD,PhD, University Hospital, Lille

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record